Autolus Therapeutics plc Total Assets 2011-2026 | AUTL

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Autolus Therapeutics plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
589 M	783 M	375 M	490 M	406 M	294 M	304 M	254 M	149 M	34.2 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
783 M	34.2 M	368 M

Quarterly Total Assets Autolus Therapeutics plc

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
662 M	721 M	746 M	827 M	854 M	901 M	406 M	-	-	-	-	-	-	406 M	-	-	350 M	294 M	317 M	311 M	338 M	304 M	315 M	346 M	-	254 M	273 M	-	-	143 M	149 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
901 M	143 M	446 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
AbbVie ABBV	134 B	$ 208.84	-2.86 %	$ 369 B	USA
AbCellera Biologics ABCL	1.36 B	$ 3.52	0.28 %	$ 1.05 B	Canada
Grifols, S.A. GRFS	21.4 B	$ 8.24	-0.12 %	$ 6.83 B	Spain
Ascendis Pharma A/S ASND	1.3 B	$ 229.25	0.44 %	$ 5 B	Danmark
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
ANI Pharmaceuticals ANIP	1.28 B	$ 74.21	-2.3 %	$ 1.43 B	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Cocrystal Pharma COCP	9.71 M	$ 1.51	48.04 %	$ 17 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
BioMarin Pharmaceutical BMRN	7.59 B	$ 55.5	-3.04 %	$ 10.6 B	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	24.2 M	-	10.36 %	$ 9.8 M	USA
Arcturus Therapeutics Holdings ARCT	271 M	$ 8.03	2.29 %	$ 220 M	Israel
Adaptive Biotechnologies Corporation ADPT	513 M	$ 14.81	2.63 %	$ 2.25 B	USA
Altimmune ALT	280 M	$ 3.34	7.05 %	$ 294 M	USA
BioNTech SE BNTX	22 B	$ 91.18	1.97 %	$ 27.2 B	Germany
Amgen AMGN	90.6 B	$ 347.94	-1.51 %	$ 187 B	USA
Aurinia Pharmaceuticals AUPH	752 M	$ 15.61	0.9 %	$ 2.1 B	Canada
Bristol-Myers Squibb Company BMY	90 B	$ 59.6	-2.45 %	$ 121 B	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Burford Capital Limited BUR	3.11 B	$ 4.14	-2.59 %	$ 683 M	Britain
BioCryst Pharmaceuticals BCRX	490 M	$ 9.02	-3.84 %	$ 1.86 B	USA
Avenue Therapeutics ATXI	2.93 M	-	-52.27 %	$ 4.45 M	USA
Atea Pharmaceuticals AVIR	315 M	$ 5.76	1.95 %	$ 469 M	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Cellectis S.A. CLLS	325 M	$ 3.41	1.19 %	$ 116 M	France
Biogen BIIB	29.4 B	$ 177.34	-3.5 %	$ 26 B	USA
Axcella Health AXLA	18.9 M	-	-16.42 %	$ 249 M	USA
Axon Enterprise AXON	4.47 B	$ 412.81	-2.54 %	$ 31.3 B	USA